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Tracking of Normal and Malignant 
Progenitor Cell Cycle Transit in a 
Defined Niche
Gabriel Pineda1, Kathleen M. Lennon1, Nathaniel P. Delos Santos1, Florence Lambert-Fliszar1, 
Gennarina L. Riso1,2, Elisa Lazzari1,3, Marco A. Marra4, Sheldon Morris1, Asako Sakaue-
Sawano5, Atsushi Miyawaki5 & Catriona H. M. Jamieson1
While implicated in therapeutic resistance, malignant progenitor cell cycle kinetics have been difficult 
to quantify in real-time. We developed an efficient lentiviral bicistronic fluorescent, ubiquitination-
based cell cycle indicator reporter (Fucci2BL) to image live single progenitors on a defined niche coupled 
with cell cycle gene expression analysis. We have identified key differences in cell cycle regulatory gene 
expression and transit times between normal and chronic myeloid leukemia progenitors that may 
inform cancer stem cell eradication strategies.
Malignant reprogramming of progenitors into self-renewing cancer stem cells (CSCs), which have a proclivity 
for dormancy in protective niches, has been implicated in therapeutic resistance of chronic myeloid leukemia 
(CML) and other CSC-driven malignancies1–5. A pressing unmet medical need for developing therapies that 
target niche dependent dormant human CSCs provides a compelling rationale for identifying key differences in 
gene expression at different cell cycle phases between live normal and malignant progenitors in a CSC-supportive 
stromal co-culture system2,6–10.
Results
Normal and Malignant Progenitor Cell Cycle Transcriptomic Analysis. To provide insights into dif-
ferences between normal and chronic phase (CP) CML progenitor cell cycle regulation, cell cycle regulatory gene 
expression changes were quantified using whole transcriptome RNA sequencing (RNA-seq) of fluorescence-ac-
tivated cell sorting (FACS)-purified CP CML, normal peripheral blood (NP), and cord blood CD34+ CD38+ 
Lin− progenitors. Agglomerative hierarchical clustering analysis (Fig. 1a), and Ingenuity® Pathway Analysis 
(IPA, QIAGEN Redwood City, www.qiagen.com/ingenuity) revealed key hubs, including CCND1, PCNA, E2F1, 
RAD51, FANCD2, and AURKB, representing cell cycle, cancer, and cellular movement associated genes that 
distinguished CP CML from normal progenitors (Fig. 1b). Of all pathways considered in RNA-seq analysis, Gene 
Set Enrichment Analysis (GSEA) revealed that the Cell Cycle and DNA Replication KEGG pathways (Nominal 
p-value < 0.001) were most enriched in CP CML compared with normal progenitors (Fig. 1c–e). An IPA was 
also performed for genes represented in a PCR cell cycle array from each RNA-seq experiment (CP and normal) 
(Supplementary Fig. 1a). In keeping with RNA-seq data, major hubs in this network represented cell cycle check 
points and DNA damage response genes (CHEK1, CHEK2, Cyclin B, RAD51, MRE11A, ATR, and ATM)11.
Lentiviral Bicistronic Fucci2BL Quantification of Cell Cycle Kinetics. Currently, few methods exist 
for quantifying cell cycle progression and analyzing regulators of gene expression in live human normal and 
malignant progenitors. To date, efficient cell cycle transit time analysis in single live human progenitors derived 
from primary patient samples has been hampered by (1) decreased cell viability following transfection or trans-
duction, (2) limited sample size, (3) dormancy of primitive progenitor populations thereby necessitating lentiviral 
rather than retroviral transduction and 4) increased apoptosis in the absence of a supportive microenvironment. 
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Current methods require genetic manipulation, sequential transduction, and clonal selection12–16. However, 
these methods and conditions are relatively inefficient for comparative studies involving primary patient 
sample-derived CSCs and their normal progenitor counterparts.
To alleviate this challenge and improve transduction efficiency, we generated a lentiviral bicistronic reporter 
vector encoding fluorescent ubiquitination-based cell cycle indicator probes (Fucci2). The Fucci2BL lentiviral 
vector expresses mVenus-hGem(1/110) fused to mCherry-hCdt1(30/120) by the T2A peptide using an EF1 pro-
moter that generates optimal levels of gene expression in progenitors17 (Fig. 2a). These fluorescent reporters 
Figure 1. RNA-seq identifies distinct differences in DNA replication and cell cycle gene expression in 
normal and chronic phase CML progenitor cells. (a) Heatmap from agglomerative hierarchical clustering 
of GSEA top ranked genes between 8 chronic phase CML (CP), 3 normal peripheral (NP) blood and 3 cord 
blood (CB) samples using RNA-seq data. Red indicates higher expression values and green indicates lower 
expression values (Log2 FPKM scale). (b) Ingenuity® Pathway Analysis performed on statistically significant 
genes (p < 0.05) between CP (n = 8) and normal (n = 6, 3 NP, 3 CB): RNA-seq expression data reveals cyclin 
D1 (CCND1) as a major hub. Arrows indicate interaction directionality. Red indicates increased expression 
and green indicates decreased expression in CP relative to NP. (c,d) Enrichment plots for KEGG Cell Cycle and 
DNA Replication pathways from Gene Set Enrichment Analysis (GSEA) between 8 CP and 6 normal (3 CB, 
3 NP) samples using RNA-seq gene expression data indicate enrichment of these pathways in CP relative to 
NP. (e) GSEA Summary table obtained from RNA sequencing data comparing 8 CP to 6 normal (3 CB, 3 NP) 
samples confirms Cell Cycle and DNA Replication pathways as significant to CP and normal differential 
expression.
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can distinguish three cell cycle phases as G1 by red fluorescence, G1/S by yellow fluorescence, and S/G2/M by 
green fluorescence. Although these reporters cannot specifically distinguish between G1 and G0 it has been pre-
viously demonstrated that red fluorescent signal intensities generated from mCherry-hCdt1(30/120) reporter 
Figure 2. Fucci2BL vector generation and characterization. (a) Diagram and map of construct design 
and generation. Both mVenus-hGem(1/110) and mCherry-hCdt1 (30/120) were subcloned into a pCDH-
EF1α -T2A lentiviral expression vector. (b) Temporal analysis of confocal images generated from lentiviral 
transduced 293A cells stably expressing fluorescent reporters. White arrows mark which cell was tracked to 
analyze cell cycle kinetics. (c) Cell cycle kinetics was determined from average fluorescence intensity from 
marked cells expressing reporters. (d) Diagram representing location of specific cell populations (mCherry+ , 
mCherry+ mVenus+ , mVenus+ ) identified by FACS analysis. (e) Live cell FACS analysis of 293A cells stably 
expressing fluorescent reporters. (f) DNA content analysis using DAPI stain on 293A cells stably expressing 
fluorescent reporters. (g) Cell cycle FACS analysis using Ki-67 staining and DAPI on 293A cells stably 
expressing fluorescent reporters. (h) Cell cycle kinetics of 293A (n = 10) cells represented in hours. (I) Duration 
of cell cycle phase represented by median (hours) for 293A (n = 10) cells.
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in particular can enrich for cells in G1 and quiescent G0 cells18. This lentiviral bicistronic vector ensures that 
ubiquitin regulated cell cycle sensors are expressed equally. Initially, the Fucci2BL vector transduction efficiency 
and the fidelity of cell cycle kinetic analysis were compared with 293A cells that were co-transduced with both 
mVenus-hGem(1/110) and mCherry-hCdt1(30/120) independent Fucci2 reporters (Supplementary Fig. 2a). 
Notably, 293A cells transduced with our Fucci2BL reporter displayed distinct nuclear staining of either green 
or red fluorescence and normal cell morphology. Transduction efficiency appeared to be higher with the single 
vector Fucci2BL compared with the standard sequential transduction schema12,19. Moreover, single transduction 
with the Fucci2BL bicistronic expression vector would be expected to better preserve primary progenitor viability. 
Next we characterized the fidelity of cell cycle in 293A cells transduced with the Fucci2BL reporter, which stably 
express mVenus-hGem(1/110) and mCherry-hCdt1(30/120), using time-lapse confocal fluorescence microscopy. 
These 293A cells revealed normal cell morphology and distinct nuclear staining of either green or red fluores-
cence depending on the cell cycle stage with red fluorescence indicating G1, yellow indicating G1/S and green flu-
orescence indicating S/G2/M (Fig. 2b; Supplementary Fig. 2b). In 293A cells, the duration of each cell cycle phase 
was determined by quantifying the average fluorescence intensity in individual live cells by confocal fluorescence 
microscopy following Fucci2BL reporter transduction (Fig. 2c,d). FACS analysis was used to quantify the per-
centage of cells in each phase of the cell cycle. Based on FACS analysis, 36.9% of cells are in G1, 20.9% in G1/S, and 
39.5% in S/G2/M (Fig. 2e). As expected, mVenus+ positive cells are in both G1 and S phase, containing double the 
DNA content of mCherry+ and mVenus+ /mCherry+ cells as represented by a two-fold increase in DAPI signal 
(Fig. 2f). Although both mVenus-hGem(1/110) and mCherry-hCdt1 (30/120) sensors have been previously char-
acterized and validated, it was important to determine both were properly regulated while expressed equally from 
the lentiviral bicistronic vector. Since the Fucci reporters can distinguish G1, G1/S, and S/G2/M cell cycle phases it 
was important to confirm the accuracy of the new reporter by comparing it to a validated method2 used to study 
cell cycle status based on Ki-67 and DAPI staining for FACS analysis. As a final method for characterizing the 
fidelity of our Fucci2BL reporter, stably transduced 293A cells were analyzed using Ki67/DAPI cell cycle FACS 
analysis. Using this approach, 36.6% of cells were found to be in G1, 20.4% in S, and 24.6% in G2/M (Fig. 2g). A 
confocal fluorescence microscopic comparison of cell cycle kinetics of normal progenitor CD34+ (NP) cells com-
pared to 293A cells revealed a trend toward prolongation of S/G2/M (Supplementary Fig. 2e). The median dura-
tion of G1 was 5.63 hours (IQR 4.5–7.5), G1/S phase was 4.08 hours (IQR 3.5–5.0), and S/G2/M was 11.13 hours 
(IQR 9.0–12.25), for 293A cells (Fig. 2h,i and Supplementary Video 1). Together, these studies demonstrated the 
high fidelity of the Fucci2BL system with regard to quantification of cell cycle kinetics in cell lines.
Molecular Characterization of Normal and Malignant Progenitor Cell Cycle Kinetics on a 
Defined Niche. Next, we addressed (1) whether clonal cell cycle kinetic differences could be resolved in live 
normal versus chronic phase progenitors, (2) whether specific gene expression changes during different phases 
of the cell cycle could be quantified, and (3) whether cell cycle kinetics differed between normal and CP CML 
progenitors in a niche-responsive manner. To this end, we transduced CD34+ selected progenitors from both 
human NP and CP CML with the Fucci2BL reporter, followed by culturing on a SL/M2-LSC stromal co-culture 
system (Supplementary Fig. 3a). On SL/M2 stroma, transduced normal CD34+ cells on average transited the cell 
cycle within 26 hours (Fig. 3a,b and Supplementary Video 2). In contrast, CP CML CD34+ cells transduced with 
Fucci2BL demonstrated a prolongation of transit through G1 (Fig. 3c,d). A minor portion was also observed 
to cycle completely through all phases of the cell cycle. Confocal fluorescent images were obtained at discrete 
intervals (0, 10hrs, 28hrs), and cell cycle kinetics of CD34+ CP CML cells was determined using average fluores-
cence intensity (Fig. 3c,d and Supplementary Video 3). Quantitative confocal fluorescence microscopic analysis 
of single normal (NP; n = 19) and CP CML (CP; n = 17) CD34+ progenitors was used to generate G1 phase 
averages (Supplementary Fig. 3c). Comparative analysis of cell cycle transit in NP versus CP CML CD34+ cells 
demonstrated that CP CD34+ CML cells (11 out of 17 cells) harbored significantly longer G1 phase transit times 
(p-value 0.0014; Fisher’s exact test) compared with normal progenitor counterparts (Supplementary Fig. 3b,c). 
Three out of the (n = 17) cells were observed to cycle completely through all phases of the cell cycle. Multi-color 
FACS analysis revealed that the majority of CP CML progenitors remained viable in stromal co-cultures used for 
confocal fluorescence microscopic imaging of cell cycle status (Supplementary Fig. 3f). Furthermore, Ki-67 and 
DAPI based-cell cycle FACS analysis confirmed that CP CML CD34+ cells transit G1-phase slowly compared with 
their normal progenitor counterparts (Supplementary Fig. 3g). To investigate transcription patterns related to the 
extended G1-phase observed in CP CML progenitors, Integrated System for Motif Activity Response Analysis 
(ISMARA) was completed on reads from CD34+ CP CML (n = 3) and NP (n = 3) samples subjected to RNA-seq 
and aligned to the GRCh37 reference genome using STAR (https://github.com/alexdobin/STAR). As an online 
tool, ISMARA identifies key transcription factors responsible for observed genome wide expression patterns 
based on computationally predicted transcription factor regulatory sites or motifs20. The top ranked motifs, des-
ignated by Z-value from approximately 200 curated motifs, were those associated with the transcription factors 
E2F1-5 (Z-value = 5.8) and TFDP1 (Z-value = 4.6), which heterodimerize and regulate the G1 to S phase transi-
tion. Activity profiles from E2F1-5 and TFDP1 indicated higher activity in CP CML cells compared to NP cells 
thereby providing a novel insight into the mechanisms governing the extended G1-phase observed in CP CML 
cells (Supplementary Fig. 3d,e).
Next, we utilized the quantitative RT2–PCR Profiler Array to monitor the response of 84 genes involved in cell 
cycle regulation, and compared CD34+ CP CML and normal progenitor cells at different phases of the cell cycle 
(Supplementary Fig. 3a). When comparing FACS-purified CP CML versus normal progenitor (n = 6 samples) 
from different phases of the cell cycle, PCR array based gene expression differences were observed in G1 and S/
G2/M cell cycle phases. Specifically, examination of the G1 cell cycle phase after 72 hours in the stromal co-culture 
system revealed 8 significantly differentially expressed genes (Fig. 3e). In the G1 (red) cell cycle phase, 7 cell cycle 
regulatory genes, including CDC20, CDKN2B, ATM, RBL2, RAD9A, CDK5RAP1, and CCNC, were significantly 
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(p < 0.05) downregulated in CP CML compared with normal progenitors. Downregulation of CDC20 may lead 
to deregulation of the APC/C complex coinciding with delayed G1/S transition observed in CP CML progenitors. 
Figure 3. Live cell imaging of stromal co-cultures distinguishes differences in cell cycle kinetics between 
chronic phase CML (CP) and normal peripheral blood (NP) CD34+ cells.  (a) Temporal analysis of confocal 
images generated from lentiviral transduced CD34+ selected NP cells grown on SL/M2 co-culture with 
bicistronic fluorescent reporter. White arrows mark which cell was tracked to analyze cell cycle kinetics.  
(b) Cell cycle kinetics was determined from average intensity of fluorescence from marked cells (white arrow) 
expressing Fucci2BL reporter. (c) Temporal analysis of confocal images generated from lentiviral transduced 
CD34+ selected (CP) cells grown on SL/M2 co-culture with bicistronic fluorescent reporter. White arrows 
mark which cell was tracked to analyze cell cycle kinetics. (d) Cell cycle kinetics was determined from average 
intensity of fluorescence from marked cells expressing reporters. (e) Volcano plot of CP CML (G1) phase 
(n = 3) differential cell cycle gene expression compared to NP (G1) phase (n = 3). Orange circles indicate genes 
expressed greater than + 1.0 Log2 fold change in CP CML (G1) vs NP (G1). Magenta circles indicate genes 
downregulated and expressed less than − 1.0 Log2 fold change in CP CML (G1) vs NP (G1). (f) Volcano plot 
of CP CML (S/G2/M) phase (n = 3) differential cell cycle gene expression compared to NP (S/G2/M) (n = 3). 
Orange and magenta indicate same nomenclature as above.
www.nature.com/scientificreports/
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Similarly key G1 checkpoint arrest genes, such as CDKN2B, RBL2, CDK5RAP1, and CCNC, coincided with the 
delayed G1/S transition observed in CP CML progenitors, which also harbored longer G1 transit times. Significant 
downregulation of both ATM and RAD9A, two key DNA damage response genes, suggests that CP CML progen-
itors in G1 phase are more susceptible to DNA damage. Analysis of the S/G2/M cell cycle phases revealed 17 dif-
ferentially expressed genes (Fig. 3f). Of these genes, MCM2 and CCNF were significantly (p < 0.05) upregulated 
in CP CML versus normal progenitor cells suggesting that two key processes that distinguished CP CML from 
normal progenitors were regulation of DNA replication and repair.
Discussion
In contrast to dormant hematopoietic stem cells, which tightly regulate DNA damage responses21–24, slowly 
cycling malignant progenitors in CML persist despite accumulation of DNA double strand breaks and unfaithful 
repair25–29. In keeping with these findings, our RNA-seq analysis revealed that KEGG cell cycle, DNA replication 
and DNA mismatch repair pathways were significantly differentially regulated between CP CML and normal 
progenitors. Together these studies provided a compelling rationale for developing reliable and robust methods 
to investigate niche-dependent and cell autonomous drivers of cell cycle transit and cell cycle regulatory gene 
expression in live normal and malignant progenitors.
Thus, we developed a lentiviral bicistronic fluorescent ubiquitination-based cell cycle indicator (Fucci2BL) 
system that enables efficient one-step transduction of normal progenitors and patient-derived malignant progen-
itors as well as real-time quantification of single live progenitor cell cycle kinetics in response to a defined niche. 
The Fucci2BL lentiviral reporter system facilitates fluorescent quantification of G1, G1/S, and S/G2/M cell cycle 
phases and real-time clonal tracking by confocal fluorescence microscopy analyses. The reporter also facilitated 
the purification of live cells in different cell cycle stages, potentially allowing for the enrichment of slow cycling 
cells, that may be resistant to therapies that target rapidly dividing cells and thus promote relapse.
Development of the single transduction Fucci2BL system enabled FACS-purification and gene expression 
profiling of human normal and CP CML progenitors in the G1 phase of the cell cycle after co-culture on a defined 
niche. In contrast to their normal progenitor counterparts, G1 CP CML progenitors showed decreased expres-
sion of DNA damage response genes required for accurate double strand DNA break repair, such as ATM and 
RAD9A30. Coupled with previous findings that BCR-ABL promotes genomic instability through DNA damage 
and inefficient recombination repair, our results suggest that decreased expression of DNA damage response 
genes in G1 phases may contribute to malignant progression and resistance29,31,32.
Distinctive niche-responsive alterations in gene expression between normal and CP CML progenitors were 
also detected in S/G2/M cell cycle phases. In particular, MCM2, a licensing factor that regulates DNA replication 
in S phase, was found to be significantly upregulated in CP CML compared with normal progenitors. Moreover, 
expression of an F box protein CCNF, which mediates genome stability through regulation of dNTP levels,33 was 
also increased in S/G2/M phase of the cell cycle in CP CML compared with normal progenitors. Cumulatively, 
these data suggest that malignant progenitors have an enhanced capacity for DNA replication despite DNA dam-
age acquired as a consequence of DNA repair defects in the G1 phase of the cell cycle. Detection and character-
ization of niche-responsive and cell autonomous regulators of cell cycle transit in live normal and malignant 
progenitors may inform development of targeted CSC eradication strategies in a broad array of malignancies and 
thus may help to obviate relapse.
As expected in confocal fluorescence microscopic imaging studies of live cells on a defined niche, cells migrate 
off the niche depending on cell cycle status. However, cells can be further analyzed by FACS and PCR array to 
determine cell cycle status and cell cycle-dependent gene expression characteristics, respectively. Notably, our 
novel Fucci2BL single cell cycle tracking system captures an important aspect of leukemia stem cell biology in 
that CP CML progenitors are more likely to adhere to the niche and take longer to transit the G0/G1 phase of the 
cell cycle compared with their normal progenitor counterparts. Finally, the Fucci2BL system will enable accurate 
real-time evaluation of small molecule inhibitors of primary human leukemia stem cell dormancy in the niche 
that promote sensitization to therapeutic agents targeting dividing cells.
Methods
Whole transcriptome RNA sequencing. RNA sequencing was performed using purified RNA from 
50,000 CD34+ selected progenitor cells from each sample type normal cord blood (n = 3), normal peripheral 
blood (n = 3), and chronic phase CML (n = 8) as described previously2,34.
Gene Set Enrichment Analysis. A Gene Set Enrichment Analysis (GSEA) using Kyoto Encyclopedia of 
Genes and Genomes (KEGG) (http://www.genome.jp/kegg/kegg1.html) gene sets was performed on 30,325 gene 
FPKM values per sample for 3 NP, 3 CB, and 8 CP CML samples, comparing CP CML samples versus the other 
samples as described previously1. A heatmap was produced from the top 75 genes by absolute GSEA feature score 
using GSEA software version 2.2.0 (http://www.broadinstitute.org/gsea).
Ingenuity Pathway Network Analysis. Log2-fold change was calculated for CP CML (n = 8) versus nor-
mal control (n = 6, 3 NP, 3 CB) samples based on RNA-seq gene expression values in FPKM, then imported to 
Ingenuity Pathway Analysis (IPA) for network assembly. For both networks genes upregulated in CP CML are 
colored red, while genes downregulated in CP CML are colored green.
Cell Culture. 293A cells were cultured in DMEM (Corning Cell Grow, cat. 10–017-CV) supplemented with 
10% (v/v) FBS (Gemini, cat. 100—106) and 1% (v/v) penicillin-streptomycin. Both M2 and SL cells were pur-
chased (StemCell Technologies). M2 cells were cultured in RPMI supplemented with 10% (v/v) FBS and produce 
both human interleukin-3 (IL-3) and human granulocyte colony stimulating factor (G-CSF). SL cells produce 
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(IL-3) and human stem cell factor (SCF). SL cells were cultured in DMEM supplemented with 10% (v/v) FBS and 
selected every three passages with 0.8 mg/ml G418 (Life Technologies, cat. 11811031), 0.125 mg/ml Hygromycin 
B (StemCell Technologies, cat. 03813). M2 cells were cultured in RPMI (GIBCO, cat 11875 93) supplemented 
with 10% (v/v) FBS and selected every three passages with 0.4 mg/ml G418, 0.06 mg/ml Hygromycin B. Primary 
patient CD34+ selected chronic phase CML and normal peripheral blood samples were cultured in Myelocult 
H5100 (StemCell Technologies, cat. 05150) supplemented with the following cytokines and ligands from R&D 
systems, 50 ng/mL stem cell factor (SCF, cat. 255-sc), 10 ng/mL Thrombopoietin (TPO, cat. 288-TP), 50 ng/mL 
fms-like tyrosine kinase-3 (FLT3, cat. 308-FK), and 10 ng/mL interleukin-6 (IL-6, cat. 206-IL) as previously 
described2,3,34,35.
Stromal Co-Culture System for Real-time Live Progenitor Cell Cycle Imaging. Confluent SL and 
M2 cells were harvested with 0.05% Trypsin (Life Technologies), and then irradiated with 8000 cGy of ionizing 
radiation. Following irradiation cells were incubated for 2 hours then counted with trypan blue and plated at a 
ratio of 1:1 at 2.5 × 105 cells/ml into Mattek 35 mm with 14 mm Microwell No.1.5 glass bottom, poly-d-lysine 
coated dishes (Part # P35GC-1.5-14-C). On day two CD34+ selected normal progenitors (NP) or chronic phase 
CML progenitors (CP) cells were plated on top of the adherent SL/M2 cells and cultured in Myelocult H5100.
Plasmid Construction. The bicistronic lentiviral Fucci2BL expression vector was generated by sub-
cloning both mVenus-hGem(1/110) and mCherry-hCdt1(30/120) into pCDH-T2A-copGFP (CD521A-1, 
SBI Systems Biosciences). The first step involved ligating the PCR product mCherry-hCdt1(30/120) into 
BspE1/SalI digested pCDH-EF1-T2A-copGFP. Ligating mCherry-hCdt1(30/120) into BspEI/SalI digested 
pCDH-T2A-copGFP in-frame replaced copGFP with mCherry-hCdt1(30/120). The second step involved ligating 
the PCR product mVenus-hGem(1/110) into XbaI/BamHI digested pCDH-EF1-T2A- mCherry-hCdt1(30/120). 
Ligating mVenus-hGem(1/110) into XbaI/BamHI digested pCDH-T2A- mCherry-hCdt1(30/120) linked 
mVenus-hGem(1/110) and mCherry-hCdt1(30/120) by 2A peptide. Both pCSII-EF- mVenus-hGem(1/110) and 
pCSII-EF-mCherry-hCdt1(30/120) were used as template for both rounds of PCR. The first round of PCR used 
forward primer: BspE1/ mCherryhCdt1 (5′ -GGA CCT TCC GGA ATG GTG AGC AAG GGC-3′ ) and reverse 
primer SalI/mCherryhCdt1 (5′ -ACG CGT CGA CTT AGA TGG TGT C-3′ ). The second round used forward 
primer: XbaI/mVenus-hGeminin (5′ -TGC TCT AGA GCC ACC ATG GTG AGC AAG GGC and reverse primer: 
BamHI/hVenusGeminin (5′ -CGG GAT CCC AGC GCC TTT CTC-3′ ). The housekeeping elongation factor 1α 
(EF1) promoter drives the expression of both mVenus-hGem(1/110) and mCherry-hCdt1(30/120) in the bicis-
tronic Fucci2BL lentiviral reporter vector. Primers used in this study synthesized by ValueGene (San Diego, CA) 
are summarized in (Supplementary Fig. 2c). Restriction enzyme analysis (Supplementary Fig. 2d) and DNA 
sequencing were used to verify Fucci2BL plasmid.
CD34+ Selection of Primary Patient Sample. Untreated chronic phase (CP) CML samples were 
obtained from patient peripheral blood that was collected with informed consent for research use in accordance 
with Institutional Review Board approved protocols at UCSD or purchased from AllCells (Alameda, CA). Normal 
peripheral blood mononuclear cells (PBMCs) were purchased from the San Diego Blood Bank. Peripheral blood 
mononuclear cells (PBMCs) were isolated by Ficoll (GE Healthcare, cat# 17-1440-03) density centrifugation and 
viable cells were stored in liquid nitrogen in freezing media. CD34+ cells were enriched from both (CP) CML 
and NP by immunomagnetic bead separation following manufacturer’s instructions (MAC; Miltenyi, Bergisch 
Gladbach, Germany) as described previously1–3,35. The selected cells were collected and resuspended in 1ml of 
MyeloCult supplemented with cytokines and cultured for 24 hours before they were counted and transduced.
Fucci2BL Transduction of CD34+ Progenitor Cells. Transduction of both normal and CML CD34+ 
enriched progenitors was performed as follows: 50,000 cells/100uL were plated in 96-well U-bottom plates in 
MyeloCult (Life Technologies) supplemented with human cytokines (IL-6 10 ng/mL, FLT3 50 ng/mL, SCF 50 ng/
mL, and TPO 10 ng/mL). Cells were transduced with a multiplicity of infection (MOI) of 200 Fucci2BL for 
72 hours.
Cell Cycle FACS Analysis. For cell cycle FACS analysis, 293A cells were harvested with Accutase (StemCell 
Technologies), and washed with 10ml PBS with 1%FBS. The cell pellet was washed with 10ml PBS and fixed with 
100 μL 1% (v/v) PFA in PBS for 15 min at 4 °C. Then, 2 mL of 70% ethanol were added dropwise while vortexing 
and cells were incubated for 2 hours at − 20 °C. Cells were then washed twice with 2 ml PBS with 1%FBS supple-
mented with 0.2% saponin. Alexa Fluor Ki67-A647 (BD Pharmingen cat# 561126 Clone B56) was diluted 1:50 
with PBS with 1%FBS supplemented with 0.2% saponin and 50 μL were added to the cells, and incubated for 
45 min at room temperature. Cells were washed with 2ml PBS with 1%FBS with 0.2% saponin and stained with 
DAPI, which was diluted 1:10,000 and incubated for 10 min at room temperature. Cells were washed with PBS 
with 1%FBS and analyzed on a FACS Fortessa analyzer.
Live Cell Staining. While 293A cells were grown in a 10 cm plate, 56 μL of 1 mg/mL Hoechst were added to 
10 mL of DMEM with 10% FBS and cells were incubated in a 37 °C incubator with 5% CO2 for 30 min. Harvested 
cells were analyzed using a FACS Fortessa. 293A cells transfected with either mCherry-hCdt1(30/120) (ex 587 em 
610) or mVenus-hGem(1/110) (ex 396/475 em 508) were used as controls.
Time lapse confocal fluorescence microscopic imaging. Confocal fluorescence images were acquired 
using the Olympus Confocal Laser Scanning Microscope Model FLUOVIEW FV10i-DOC equipped with 
UPLSAP10X/0.4-NA objective and stage top incubator (cat# INUG2-FV10i, TOKAI HIT, Japan). The Digital 
Gas Mixer maintained a humidified atmosphere at 37 °C, with 5% CO2. Images were taken with an image size 
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1024 × 1024(pixel), Balance (× 4) speed & quality (average), × 2.5 confocal aperture with crosstalk correction on. 
The excitation spectral values were as follows: ex 473 nm (power at 4.9%, green channel) and ex 559 nm (power 
at 4.9%, red channel). Emission spectral ranges were as follows: Green-Narrow Em490–540 and Red-Narrow 
Em570-620. Time-lapse imaging was acquired taking phase contrast, red and green fluorescent recorded 
images every 15 minutes for over 30 hours of imaging for each NP and CP CML co-cultures. After completion 
of time-lapse imaging an animation was complied with all images acquired every 15 minutes. Cell cycle kinetics 
of both NP and CP CML cells was determined using Olympus Fluoview Ver.2.1c analysis software. Single cells 
were tracked independently throughout animation and single measurements were made from images taken every 
15 minutes. Specifically, measurements were made using analysis tools by defining a region of interest (ROI) using 
the tool view window on each individual cell. The average red and green intensity was recorded from every image 
throughout the entire time-lapse animation. Cell cycle kinetics were determined by plotting average red and 
green fluorescent intensity over time using Prism software. The Fluoview FV10i raw images were reconstructed 
using ImageJ Software.
Cell Cycle PCR Array. Freshly sorted cells were collected directly into RLT lysis buffer (Qiagen, Germantown, MD). 
RNA was purified using RNeasy extraction kit with an on column DNase digest step to remove trace genomic 
DNA present. RNA concentrations were determined using a NanoDrop 2000 spectrophotometer (Thermo 
Scientific). RNA was stored in − 80 °C until all samples were sorted and purified. Equal amounts of RNA (16ng/
sample) were converted into cDNA using the First Strand cDNA Synthesis (Qiagen) kit. Due to individual sample 
RNA concentrations of 1–13 ng/μL, a Preamplification of cDNA Target Templates for the RT2 Profiler PCR Cell 
Cycle Array (Qiagen) was completed. The PCR Array profiled the expression of 84 cell cycle genes, 5 house-
keeping genes, controls for genomic DNA contamination, and efficiency of both the (RT-PCR: PCR) reactions. 
Cycling conditions for amplification of cDNA from fresh/frozen samples were followed according to manufac-
tures protocol. Cell cycle gene expression was determined using the BioRad CFX96 system (UCSD Human Stem 
Cell Core Facility).
Statistical analysis. Statistical analyses were performed with Microsoft Excel, R, Graphpad Prism software, 
and SAS statistical software.
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